Fox Chase Cancer Center News

PHILADELPHIA (October 21, 2018) – A new analysis of nearly 600 men who received brachytherapy for prostate cancer shows that overall incidence of complications related to the procedure within four months of treatment is less than 20 percent. All patients were treated at Fox Chase Cancer Center.

PHILADELPHIA (October 10, 2018)— Using a detailed analysis comparing the genetic and molecular makeup of tumors from nearly 1,000 patients with four common mouse models of hepatocellular carcinoma (HCC), researchers have identified animal models that most closely mimic human disease. 

PHILADELPHIA (October 4, 2018) – Jose Russo, MD, FACP, director of the Irma H. Russo, MD, Breast Cancer Research Lab at Fox Chase Cancer Center, named by AL DÍA as one of nine recipients of their Hispanic Heritage Award for 2018.

PHILADELPHIA (October 2, 2018) — Observing how cells of the intestinal epithelium respond to Salmonella, scientists at Fox Chase Cancer Center have found a novel mechanism of cell death that shows a way to control the spread of bacteria.

PHILADELPHIA (October 2, 2018) – Fox Chase Cancer Center will again field a team  to raise funds at the Pancreatic Cancer Action Network (PanCAN) PurpleStride Philadelphia. The event will be held on Saturday, November 3 at Memorial Hall in Fairmount Park.

PHILADELPHIA (October 1, 2018) – October is Breast Cancer Awareness month. Fox Chase Cancer Center reminds women to schedule their screening test for breast cancer—the most reliable way to detect breast cancer early, when the disease is most treatable.

Philadelphia (September 28, 2018) – Fox Chase Cancer Center is pleased to announce that its scientists and clinicians earned several newly issued patents during fiscal years 2017 and 2018, the latter of which ended June 30, 2018.

PHILADELPHIA (September 25, 2018)— In addition to impacting cancer risk, mutations in the BRCA1 gene also have a role in determining whether a patient responds to certain types of therapies. In a new publication, Neil Johnson, PhD, found that cancers with different types of BRCA1 mutations have varying susceptibilities to biological pathways that induce resistance to PARP inhibitors, an emerging class of cancer drugs